# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Reuters
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate.
-SEC Filing
- SEC Filing
- SEC Filing